SEHK:1177Pharmaceuticals
Sino Biopharmaceutical (SEHK:1177) Is Up 5.0% After Advancing ROCK2 Drug TDI01 To Phase III - Has The Bull Case Changed?
Sino Biopharmaceutical’s board previously reported enrollment of the first patient in a global first Phase III trial of TDI01, a highly selective ROCK2 inhibitor for idiopathic pulmonary fibrosis, following encouraging Phase II efficacy and safety data.
The same molecule has also entered Breakthrough Therapy Designation review in China for chronic graft-versus-host disease, underlining its potential relevance across multiple serious immune-related conditions.
We’ll now examine how advancing...